Last updated: February 19, 2026
This analysis details the scope and claims of Argentina drug patent AR040682 and examines its patent landscape.
What is the Core Invention Protected by AR040682?
Argentina patent AR040682, filed on November 19, 2003, and granted on September 17, 2008, protects a process for preparing substituted benzimidazoles [1]. The patent specifically covers a method for synthesizing compounds that are pharmacologically active and useful as proton pump inhibitors (PPIs). These PPIs are primarily used to treat acid-related gastrointestinal disorders such as peptic ulcers and gastroesophageal reflux disease (GERD). The core invention lies in an improved, efficient, and cost-effective synthetic route that yields these valuable pharmaceutical compounds.
What Specific Claims Does AR040682 Encompass?
The claims of AR040682 define the exclusive rights granted to the patent holder. The patent's claims are directed towards the process of manufacturing specific substituted benzimidazoles, rather than the final drug compounds themselves. This distinction is critical for understanding potential infringement and market entry strategies for generic manufacturers.
Claim 1 is the most central and broadly defines the protected process. It describes:
- A process for preparing a substituted benzimidazole of formula (I), which is characterized by reacting a 2-mercaptobenzimidazole derivative with an activated pyridine derivative [1].
The patent further specifies the chemical structures of the starting materials and intermediates, and the reaction conditions, including temperature, solvents, and catalysts. The claims also cover variations in the substituents on the benzimidazole and pyridine rings, allowing for the synthesis of a range of PPIs.
Key elements within the claims include:
- Specific Chemical Structures: Detailed depiction of the molecular structures of the reactants and the resulting substituted benzimidazole.
- Reaction Steps: A defined sequence of chemical transformations.
- Reagents and Solvents: Specification of the chemicals and reaction media used.
- Intermediate Compounds: Protection extends to key intermediate molecules formed during the synthesis.
- Purification Methods: The claims may also implicitly or explicitly cover methods to purify the final product, ensuring its pharmaceutical grade.
The exact wording and scope of each claim are crucial. For instance, a claim might specify a particular range of temperatures or a list of acceptable solvents. Any manufacturing process that utilizes the steps, reagents, or intermediates described in these claims could be considered infringing.
What is the Pharmaceutical Significance of the Compounds Synthesized by AR040682?
The substituted benzimidazoles produced by the process described in AR040682 are a class of drugs known as proton pump inhibitors (PPIs). These drugs are among the most widely prescribed medications globally due to their efficacy in reducing gastric acid production.
The primary therapeutic applications include:
- Treatment of Peptic Ulcers: Including gastric and duodenal ulcers.
- Management of GERD: Alleviating symptoms like heartburn and regurgitation.
- Eradication of Helicobacter pylori: Often used in combination with antibiotics.
- Prevention of NSAID-Induced Ulcers: Protecting the stomach lining for patients taking nonsteroidal anti-inflammatory drugs.
The development of efficient and scalable synthetic processes for these drugs is economically significant, as it impacts manufacturing costs, drug accessibility, and market competition. Patent protection for such processes is a key strategy for pharmaceutical companies to recoup R&D investments and maintain market exclusivity.
Who is the Patent Holder of AR040682?
The patent holder for AR040682 is Laboratorios Bagó S.A., an Argentinian pharmaceutical company with a significant presence in Latin America. Laboratorios Bagó has a portfolio of patented pharmaceutical products and processes, and AR040682 represents an investment in its synthetic chemistry capabilities for producing high-demand therapeutic agents.
What is the Current Status of AR040682?
Argentina patent AR040682 was granted on September 17, 2008. Patents in Argentina typically have a term of 20 years from the filing date, provided that annual maintenance fees are paid.
- Filing Date: November 19, 2003
- Grant Date: September 17, 2008
- Term Expiration (estimated): November 19, 2023 (20 years from filing)
Given the filing date of November 19, 2003, and a standard 20-year patent term, the patent for AR040682 is likely expired or nearing its expiration date. Companies looking to enter the market with generic versions of the drugs synthesized by this process should verify the exact expiration date and confirm the absence of any supplementary protection certificates or other extensions.
What is the Patent Landscape Surrounding AR040682?
The patent landscape for PPIs is complex, characterized by numerous patents covering active pharmaceutical ingredients (APIs), formulations, polymorphs, and manufacturing processes. AR040682 specifically targets a manufacturing process.
Companies operating in this space face several considerations:
- Process Patents vs. Composition of Matter Patents: AR040682 is a process patent. This means that while Laboratorios Bagó has exclusive rights to its specific method of synthesis, other companies may be able to legally produce the same API using a different, non-infringing synthetic route.
- Generics Market Entry: The expiration of AR040682 will remove one layer of patent protection for the synthesis of these benzimidazoles. However, generic manufacturers must still ensure they do not infringe on other existing patents, such as:
- Composition of Matter Patents: Patents covering the specific API itself (if still in force).
- Formulation Patents: Patents covering specific dosage forms, delivery systems, or combinations with other active ingredients.
- Polymorph Patents: Patents protecting specific crystalline forms of the API that may offer improved stability or bioavailability.
- Other Process Patents: There may be other patents covering alternative or improved synthetic routes that remain in force.
- Freedom-to-Operate (FTO) Analysis: Any company intending to manufacture or market a drug synthesized via a process similar to that claimed in AR040682 must conduct a thorough FTO analysis. This involves identifying all relevant patents and assessing the risk of infringement.
- Prior Art: The existence of AR040682 and other related patents can influence the patentability of new processes. If a new process is significantly similar to what is already disclosed or claimed, it may be rejected for lack of novelty or inventiveness.
- Global Patent Strategies: Pharmaceutical companies typically file patents in multiple jurisdictions. While AR040682 is specific to Argentina, parallel patent filings in other major markets (e.g., US, Europe, Japan) would have governed market entry and exclusivity in those regions.
The expiration of a key process patent like AR040682 can signal an increased opportunity for generic competition, provided that the underlying API and formulations are also off-patent or can be manufactured without infringing other existing intellectual property rights.
Key Takeaways
- Argentina patent AR040682 protects a specific process for synthesizing substituted benzimidazoles, primarily used as proton pump inhibitors (PPIs).
- The patent was granted to Laboratorios Bagó S.A.
- The patent term is estimated to have expired or is nearing expiration, based on its filing date of November 19, 2003, and a 20-year term.
- While AR040682 protected a manufacturing process, generic manufacturers must still conduct comprehensive freedom-to-operate analyses to avoid infringing on other patents covering the API, formulations, or alternative synthetic routes.
Frequently Asked Questions
-
Can a generic company use the exact process described in AR040682 now that the patent has expired?
A generic company can use the process if the patent has indeed expired and if no other patents covering the same process or essential steps remain in force in Argentina. A thorough legal review is necessary.
-
Does the expiration of AR040682 mean the underlying drug is now freely available?
The expiration of a process patent does not automatically free the drug. The drug's active pharmaceutical ingredient (API) may be protected by its own composition of matter patent, and specific formulations or polymorphs may also be patented.
-
What is the difference between a process patent and a composition of matter patent for a drug?
A process patent protects the method of making a compound, while a composition of matter patent protects the compound itself, regardless of how it is made.
-
What does "Freedom-to-Operate" (FTO) analysis entail in this context?
An FTO analysis is a legal evaluation to determine if a proposed product or process infringes on any existing patents owned by third parties. It involves searching and analyzing relevant patent literature.
-
How does AR040682 relate to similar patents in other countries?
AR040682 is specific to Argentina. Companies typically seek patent protection for their inventions in multiple countries. The landscape in other jurisdictions would be governed by corresponding patents filed there.
Citations
[1] Laboratorios Bagó S.A. (2008). Proceso para la preparacion de benzimidazoles sustituidos. Argentina Patent AR040682.
